Clinical Laserthermia Systems AB (CLSB)

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG Thermal Therapy Systems, including ThermoguideTM Workstation and sterile disposables, for minimally invasive laser ablation of soft tissue, cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. CLS aims at expanding the current approvals to also include treatment with imILT, the Companys interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal treatment effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B

Focal laser ablation,prostate cancer treatment,and neurosurgery

Clinical laserthermia systems ab (clsb) operates in the Medical equipment manufacturing industry.

Clinical laserthermia systems ab (clsb)'s revenue is 1m - 10m

Clinical laserthermia systems ab (clsb) has 11 - 50 employees.